NCT05281926 A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients Status UNKNOWN Phase PHASE1
NCT05280444 Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma Status UNKNOWN Phase PHASE2/PHASE3
NCT05278195 Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers Status UNKNOWN Phase N/A
NCT05276037 Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates Status RECRUITING Phase N/A
NCT05263830 Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy Status RECRUITING Phase N/A
NCT05257694 Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning Status RECRUITING Phase N/A
NCT05257590 CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma Status RECRUITING Phase PHASE2
NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Status TERMINATED Phase PHASE2
NCT05250895 BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy Status COMPLETED Phase EARLY_PHASE1
NCT05250843 TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC Status RECRUITING Phase PHASE2/PHASE3
NCT05249569 Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma Status TERMINATED Phase PHASE2
NCT05242237 Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform Status UNKNOWN Phase N/A
NCT05240404 Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma Status UNKNOWN Phase PHASE2
NCT05233358 HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure Status UNKNOWN Phase NA
NCT05233098 TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. Status COMPLETED Phase N/A